Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target

$461.68 +23.28 (+5.31%)

Closing price 04:00 PM Eastern

Extended Trading

$462.00 +0.32 (+0.07%)

As of 07:57 PM Eastern

Vertex Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 28 Analyst Ratings

Sell
1

Hold
10

Buy
17

Based on 28 Wall Street analysts who have issued ratings for Vertex Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 28 analysts, 1 has given a sell rating, 10 have given a hold rating, 16 have given a buy rating, and 1 has given a strong buy rating for VRTX.

Consensus Price Target

$502.58
8.86% Upside

According to the 28 analysts' twelve-month price targets for Vertex Pharmaceuticals, the average price target is $502.58. The highest price target for VRTX is $586.00, while the lowest price target for VRTX is $408.00. The average price target represents a forecasted upside of 8.86% from the current price of $461.68.

Get the Latest News and Ratings for VRTX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Vertex Pharmaceuticals and its competitors.

VRTX Analyst Ratings Over Time

Type	Current Forecast 2/1/24 to 1/31/25	1 Month Ago 1/2/24 to 1/1/25	3 Months Ago 11/3/23 to 11/2/24	1 Year Ago 2/1/23 to 2/1/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	16 Buy rating(s)	17 Buy rating(s)	17 Buy rating(s)	13 Buy rating(s)
Hold	10 Hold rating(s)	10 Hold rating(s)	9 Hold rating(s)	6 Hold rating(s)
Sell	1 Sell rating(s)	3 Sell rating(s)	3 Sell rating(s)	3 Sell rating(s)
Consensus Price Target	$502.58	$494.04	$492.50	$389.96
Forecasted Upside	8.86% Upside	22.68% Upside	4.54% Upside	-10.12% Downside
Consensus Rating	Moderate Buy	Moderate Buy	Hold	Hold

VRTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

VRTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Vertex Pharmaceuticals Stock vs. The Competition

Type	Vertex Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.61	2.81	2.53
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	8.17% Upside	14,141.56% Upside	11.35% Upside
News Sentiment Rating	Positive News See Recent VRTX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
1/31/2025	William Blair 1 of 5 stars		Reiterated Rating	Outperform
1/31/2025	Cantor Fitzgerald 4 of 5 stars	Olivia Brayer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$480.00 ➝ $480.00	+3.69%
1/31/2025	Scotiabank 5 of 5 stars	G. Harrison Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Sector Perform ➝ Sector Perform	$430.00 ➝ $433.00	-5.82%
1/31/2025	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Andrew Fein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$535.00 ➝ $550.00	+25.46%
1/31/2025	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Joseph Stringer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
1/30/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Mohit Bansal Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$460.00 ➝ $460.00	+4.19%
1/27/2025	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Christopher Raymond Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$535.00 ➝ $533.00	+20.72%
12/23/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$550.00 ➝ $460.00	+16.19%
12/23/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$503.00 ➝ $500.00	+25.86%
12/20/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Wang Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Equal Weight ➝ Equal Weight	$509.00 ➝ $418.00	+4.39%
Get the Latest News and Ratings for VRTX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
12/20/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$566.00 ➝ $520.00	+32.36%
12/19/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
12/19/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$545.00 ➝ $522.00	+34.41%
12/16/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$490.00 ➝ $494.00	+6.53%
12/9/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$500.00 ➝ $550.00	+19.02%
11/14/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$575.00	+16.25%
11/6/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Sell ➝ Sell	$361.00 ➝ $408.00	-17.00%
11/5/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Bristow Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$562.00 ➝ $586.00	+17.77%
11/5/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Sector Perform ➝ Sector Perform	$437.00 ➝ $451.00	-8.68%
11/5/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$473.00 ➝ $476.00	-0.83%
10/10/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Brill Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
8/2/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$450.00 ➝ $558.00	+13.08%
7/23/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$450.00 ➝ $500.00	+1.60%
6/27/2024	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Chesney Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$545.00	+14.98%
6/17/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$465.00 ➝ $550.00	+15.48%
4/11/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	In-Line ➝ Outperform	$438.00	+10.17%
2/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$515.00	+23.24%
2/2/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
1/31/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Neutral ➝ Underperform	$325.00	-25.27%
1/31/2024	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
6/26/2023	888 Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Reiterates
5/25/2023	Westpark Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold
2/8/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$374.00 ➝ $365.00	+18.30%
2/8/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$374.00 ➝ $365.00	+18.30%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 11:10 PM ET.

Should I Buy Vertex Pharmaceuticals Stock? VRTX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, January 25, 2025. Please send any questions or comments about these Vertex Pharmaceuticals pros and cons to contact@marketbeat.com.

Vertex Pharmaceuticals
Bull Case

Here are some ways that investors could benefit from investing in Vertex Pharmaceuticals Incorporated:

Vertex Pharmaceuticals Incorporated recently reported earnings of $4.38 per share, exceeding analysts' expectations of $3.61, indicating strong financial performance and potential for growth.
The company's revenue for the latest quarter was $2.77 billion, surpassing expectations and showing an 11.6% increase compared to the same quarter last year, which reflects robust demand for its products.
Vertex Pharmaceuticals Incorporated has a market capitalization of $108.68 billion, suggesting it is a well-established player in the biotechnology sector, which can provide stability to investors.
Current stock price is $439.73, which has shown resilience with a recent trading increase of 2.7%, indicating positive market sentiment.
Analysts have a consensus rating of "Moderate Buy" with an average price target of $490.38, suggesting potential upside for investors based on future performance expectations.

Vertex Pharmaceuticals
Bear Case

Investors should be bearish about investing in Vertex Pharmaceuticals Incorporated for these reasons:

The stock has a price-to-earnings ratio of -212.06, indicating that the company is currently not profitable, which can be a red flag for potential investors.
Vertex Pharmaceuticals Incorporated has a negative return on equity of 1.91% and a negative net margin of 4.52%, suggesting inefficiencies in generating profit from its equity and overall operations.
Despite recent positive earnings, analysts anticipate a projected earnings per share of -1.9 for the current fiscal year, indicating potential challenges ahead.
The stock has a beta of 0.40, which suggests lower volatility compared to the market; however, this could also mean limited growth potential in a bullish market.
Institutional investors and hedge funds own 90.96% of the company's stock, which may limit the influence of retail investors and could lead to volatility based on institutional trading decisions.

VRTX Forecast - Frequently Asked Questions

: According to the research reports of 28 Wall Street equities research analysts, the average twelve-month stock price forecast for Vertex Pharmaceuticals is $502.58, with a high forecast of $586.00 and a low forecast of $408.00.
: 28 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last twelve months. There is currently 1 sell rating, 10 hold ratings, 16 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" VRTX shares.
: According to analysts, Vertex Pharmaceuticals's stock has a predicted upside of 8.86% based on their 12-month stock forecasts.
: Over the previous 90 days, Vertex Pharmaceuticals's stock had 2 upgrades and 2 downgrades by analysts.
: Vertex Pharmaceuticals has been rated by research analysts at Bank of America, Barclays, BMO Capital Markets, Canaccord Genuity Group, Cantor Fitzgerald, Citigroup, HC Wainwright, Jefferies Financial Group, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Oppenheimer, Piper Sandler, Royal Bank of Canada, Scotiabank, Stifel Nicolaus, Truist Financial, UBS Group, Wells Fargo & Company, and William Blair in the past 90 days.
: Analysts like Vertex Pharmaceuticals less than other "medical" companies. The consensus rating score for Vertex Pharmaceuticals is 2.61 while the average consensus rating score for "medical" companies is 2.81. Learn more on how VRTX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

This page (NASDAQ:VRTX) was last updated on 1/31/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target